Healthcare companies sell predictability: demand grows demographically, revenue is often regulated and therefore crisis-resistant. Consolidators — from clinic groups and MVZ platforms to private equity — actively look for acquisitions with stable staff and secured approvals.
The valuation range is wide because business models differ greatly: a care service is priced differently from a medical-device manufacturer or a laboratory. The value drivers are the same everywhere — staff retention, utilisation, approvals and independence from the owner as practitioner or key figure.
In the sale process, regulation and sponsor structures need clarifying early. We know what buyers scrutinise and prepare approvals, contracts and compliance topics before they become negotiation issues.
